New drug duo targets 'Undruggable' cancer mutations
NCT ID NCT02079740
Summary
This study is testing the safety and effectiveness of combining two oral drugs, trametinib and navitoclax, for patients with advanced solid tumors that have spread and have specific KRAS or NRAS genetic mutations. The goal is to find the best dose and see if the combination can stop or shrink tumors. The trial enrolled 96 adults whose cancer has progressed after at least one prior treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.